FDA Provides Orphan Drug Designation To X4 Pharmaceuticals' Mavorixafor To Treat Congenital
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=919722
X4 Pharmaceuticals got official permission to develop a medicine for a rare disease, which means the government thinks it's worth supporting with special help and faster approval. This is a positive sign that the company's science might work, but it doesn't guarantee the medicine will actually succeed or make money.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.